Abstract:Background and purpose J147, a novel neurotrophic compound, was originally developed to treat aging-associated neurological diseases. Based on the broad spectrum of cytoprotective effects exhibited by this compound, we investigated whether J147 has cerebroprotection for acute ischemic stroke and whether it can enhance the effectiveness of thrombolytic therapy with tissue plasminogen activator (tPA). Methods Rats were subjected to transient occlusion of the middle cerebral artery (tMCAO) by insertion of an intraluminal suture or embolic middle cerebral artery occlusion (eMCAO), and treated intravenously with J147 alone or in combination with tPA. Results We found that J147 treatment significantly reduced infarct volume when administered at 2 h after stroke onset in the tMCAO model, but had no effect in eMCAO without tPA. However, combination treatment with J147 plus tPA at 4 h after stroke onset significantly reduced infarct volume and neurological deficits at 72 h after stroke compared with saline or tPA alone groups in the eMCAO model. Importantly, the combination treatment significantly reduced delayed tPA-associated brain hemorrhage and secondary microvascular thrombosis. These protective effects were associated with J147-mediated inhibition of matrix metalloproteinase-9 (MMP9), 15-lipoxygenase-1, and plasminogen activator inhibitor (PAI) expression in the ischemic hemispheres (predominantly in ischemic cerebral endothelium). Moreover, the combination treatment significantly reduced circulating platelet activation and platelet-leukocyte aggregation compared with saline or tPA alone groups at 24 h after stroke, which might also contribute to reduced microvascular thrombosis and neuroinflammation (as demonstrated by reduced neutrophil brain infiltration and microglial activation). Conclusion Our results demonstrate that J147 treatment alone exerts cerebral cytoprotective effects in a suture model of acute ischemic stroke, while in an embolic stroke model co-administration of J147 with tPA reduces delayed tPA-induced intracerebral hemorrhage and confers cerebroprotection. These findings suggest that J147-tPA combination therapy could be a promising approach to improving the treatment of ischemic stroke.

Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant Adamts 13

Recombinant ADAMTS13 Reduces Tissue Plasminogen Activator‐induced Hemorrhage after Stroke in Mice

Tissue plasminogen activator expression and barrier properties of human brain microvascular endothelial cells.

Treatment of acute cerebral thrombosis with a novel mutated tissue plasminogen activator

The Janus face of endogenous neuronal tPA: promoting self-protection and worsening the death of neighboring neurons

Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment

Multi-mode MRI-based Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator(rtpa)reduces Hemorrhagic Transformation in Ischemic Stroke Patients

Recombinant tissue plasminogen activator protects neurons after intracerebral hemorrhage through activating the PI3K/AKT/mTOR pathway

Subacute Intranasal Administration of Tissue Plasminogen Activator Improves Stroke Recovery by Inducing Axonal Remodeling in Mice.

The paradox of tPA in ischemic stroke: tPA knockdown following recanalization improves functional and histological outcomes

Neutrophil migration participates in the side effect of recombinant human tissue plasminogen activator

Neutrophil extracellular traps contribute to tissue plasminogen activator resistance in acute ischemic stroke

Tissue-Type Plasminogen Activator Has A Neuroprotective Effect In The Ischemic Brain Mediated By Neuronal Tnf-Alpha

Tissue-type plasminogen activator has a neuroprotective effect in the ischemic brain mediated by neuronal TNF-α.

Influence of Thrombolysis on the Safety and Efficacy of Blocking Platelet Adhesion or Secretory Activity in Acute Ischemic Stroke in Mice

Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke

Single- and two- chain tissue type plasminogen activator treatments differentially influence cerebral recovery after stroke

Combination Treatment With N-Acetyl-Seryl-Aspartyl-Lysyl-Proline and Tissue Plasminogen Activator Provides Potent Neuroprotection in Rats After Stroke

tPA supplementation preserves neurovascular and cognitive function in Tg2576 mice

J147 Reduces tPA-Induced Brain Hemorrhage in Acute Experimental Stroke in Rats

Receptor-associated protein promotes t-PA expression, reduces PAI-1 expression and improves neurorecovery after acute ischemic stroke.